Pharma: Page 26
-
Mario Tama via Getty Images
J&J antidepressant eases symptoms, improves sleep in key trial
The company has put high expectations on the drug, an orexin-2 antagonist called seltorexant, as a cornerstone of its neuropsychiatry pipeline.
By Ned Pagliarulo • May 29, 2024 -
Getty Images
Can robots break the cell therapy bottleneck?
A partnership between cell therapy delivery specialist Portal Biotechnologies and precision robotics maker Multiply Labs could address manufacturing hurdles, the CEOs said.
By Michael Gibney • May 29, 2024 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Mario Tama via Getty Images
J&J gains another bispecific antibody with $1.25B skin drug buy
The deal is J&J’s second this month involving bispecific antibodies, which the company has prioritized to build its immune and cancer drug pipeline.
By Ben Fidler • May 28, 2024 -
Getty Images
Roche’s Sabry retires; Duchenne drug fails confirmatory test
The veteran executive will be replaced by Boris Zaïtra. Elsewhere, Nippon Shinyaku shared negative Phase 3 data and Merck unveiled new breast cancer results for Keytruda.
By BioPharma Dive staff • May 28, 2024 -
Getty Images
Sponsored by CognizantThe future of medicine: AI’s role in uncovering new drugs
Artificial intelligence (AI) has sparked a revolution in the pharmaceutical industry, reshaping the way we approach complex biological challenges.
May 28, 2024 -
Getty Images
Pfizer expands cost cuts with new $1.5B target
The company, which previously announced plans to trim $4 billion in spending by the end of 2024, aims to save another $1.5 billion over the next three years.
By Ned Pagliarulo • May 22, 2024 -
Getty Images
Regeneron faces new biosimilar threats; an AI biotech lays off staff
Today’s rundown also includes news of an expanded partnership for Boehringer Ingelheim and updates to emerging medicines from GSK and Bristol Myers.
By BioPharma Dive staff • May 22, 2024 -
Christopher Furlong via Getty Images
AstraZeneca’s $80B sales plan leans on cancer drug expansion
The drugmaker aims to catch up in developing new tumor-fighting technologies — areas where it has lagged behind leaders like Novartis and J&J.
By Jonathan Gardner • May 21, 2024 -
AstraZeneca sets sights on $80B in revenue by 2030
The U.K. pharma expects to launch 20 new drugs by then, among them complex medicines for cancer as well as treatments for weight loss.
By Jonathan Gardner • May 21, 2024 -
Getty Images
Erasca restructures; Novartis moves to complete MorphoSys deal
The cancer biotech is laying off one-fifth of its staff and scrapping three drugs. Elsewhere, Novartis secured sufficient support for its $3 billion buyout and Bristol Myers won a new CAR-T approval.
By BioPharma Dive staff • May 17, 2024 -
Courtesy of Roche
Roche keeps pace in obesity drug field with early study data
A drug Roche acquired in a buyout of Carmot Therapeutics and that works similarly to Zepbound helped people lose nearly 19% of their body weight in a Phase 1 trial.
By Jonathan Gardner • May 16, 2024 -
Mario Tama via Getty Images
J&J to buy Proteologix and its dual-targeting antibody drugs for $850M
The deal is part of a plan by J&J to build a portfolio of “differentiated” bispecific antibodies, an increasingly popular area of drug development.
By Kristin Jensen • May 16, 2024 -
Andreas Rentz via Getty Images
Bayer details layoffs as company shake-up continues
The reduction of 1,500 roles in the first quarter is part of CEO Bill Anderson’s plan to shrink Bayer’s bureaucracy and “radically realign” its culture.
By Delilah Alvarado • May 14, 2024 -
Getty Images
Sponsored by Almac GroupPartnering for success: Choosing the right CDMO in pharma outsourcing
Explore the four most important qualities for choosing a dependable outsourcing partner in pharma.
May 13, 2024 -
Getty Images
iTeos shares jump on TIGIT update; Acelyrin swaps CEOs
Interim data surpassed expectations, iTeos said. Bluebird bio, meanwhile, gave a fuller accounting of launch progress for its gene therapies Lygenia, Zynteglo and Skysona.
By BioPharma Dive staff • May 10, 2024 -
Maddie Meyer via Getty Images
FDA delays decision on Moderna RSV vaccine
The regulator cited “administrative constraints,” rather than any issue with Moderna’s trial data, for missing a May 12 deadline, the company said.
By Delilah Alvarado • May 10, 2024 -
Carsten Koall via Getty Images
Novavax gets a lifeline with Sanofi vaccine pact
Sanofi will ally with the under-pressure biotech, paying $500 million upfront for rights to co-commercialize Novavax’s COVID shot and develop combination influenza vaccines.
By Ned Pagliarulo • May 10, 2024 -
Getty Images
Takeda targets ‘efficiency’ in restructuring, pipeline cuts
Among the pipeline changes is a decision by Takeda to terminate studies in blood cancer of TAK-007, a CAR-NK therapy, and to pivot instead to autoimmune conditions.
By Ned Pagliarulo • Updated May 10, 2024 -
Adeline Kon / BioPharma Dive/BioPharma Dive
Deep Dive // Patent thicketsDrug patents protect pharma profits. Track when they’ll expire.
AbbVie reached legal settlements delaying the arrival of generic versions of Rinvoq until 2037, enabling four more years of exclusivity for a drug that banked about $6 billion in sales in 2024.
By Jonathan Gardner • Updated April 9, 2025 -
Sean Gallup via Getty Images
AstraZeneca withdraws COVID-19 vaccine, citing declining demand
The move ends a turbulent saga for AstraZeneca, which successfully developed a coronavirus shot but struggled to sell it amid competition and the emergence of rare but serious side effects.
By Delilah Alvarado • May 8, 2024 -
Jacob Bell/BioPharma Dive
FDA sets date for advisory meeting on Lilly’s closely watched Alzheimer’s drug
After delaying an approval decision for Lilly’s donanemab, the agency now intends to hold an advisory committee meeting on June 10.
By Jacob Bell • May 7, 2024 -
Christopher Furlong via Getty Images
AstraZeneca ups stake in Cellectis in latest cell therapy bet
The British drugmaker, which has made genetic medicine a larger priority of late, added $140 million to a deal to develop up to 10 gene and cell therapies.
By Jonathan Gardner • May 6, 2024 -
Getty Images
Sponsored by Worldwide Clinical TrialsMaximizing efficiency in translational medicine with an on-site pharmacy
The ability to modify drug formulations in real time and dosage strengths is crucial, while adhering to all regulatory standards and maintaining cGMP standards.
May 6, 2024 -
Mario Tama via Getty Images
Amgen shares soar as executives outline obesity drug push
The company said data for its Wegovy competitor was promising enough to move the drug into late-stage testing, triggering a stock jump that added billions to Amgen’s market value.
By Jonathan Gardner • May 3, 2024 -
Why selling to Novartis made sense for Mariana
Conversations at this year's J.P. Morgan Healthcare Conference led to a $1 billion buyout that Mariana's CEO described as a "perfect marriage."
By Ned Pagliarulo • May 3, 2024
Previous
